Topic: "PHARMACEUTICALS"

December 1, 2016 3 min to read

Behind the EpiPen

Category : Pharma year in review

As headlines screamed controversy, a quiet evolution continued in drug pricing Rick Mullin Mylan CEO Heather Bresch holds up EpiPens at the House Oversight & Government Reform Committee hearing, “Reviewing the Rising Price of EpiPens,” on Capitol Hill in Washington, D.C., Sept. 21. Credit: Michael Reynolds/EPA/Newscom Again i...

December 1, 2016 1 min to read

Pharmaceutical firms saw mixed year in 2016

Category : Pharma year in review

Sales rose for most U.S. firms, fell at three of Europe’s big drug makers Ann M. Thayer Although overall sales expanded in 2016 for the top 10 drug companies, they were clearly split between those that grew and those that didn’t. With four of them seeing sales declines, the ranking got shuffled. Fortunes were divided to some exte...

December 1, 2016 1 min to read

AbbVie’s Humira held onto top spot despite biosimilar threat

Category : Pharma year in review

Drug is one of several biologics that dominated pharmaceutical sales in 2016 Ann M. Thayer Among the top 10 pharmaceutical products in 2016, biologics beat out small molecules, and treatments for cancer and inflammation dominated the field. Holding the lead again was Humira, a monoclonal antibody targeting inflammatory and autoimmune...